SeekingAlpha · Aug 5, 2026
Bioventus Inc. 2026 Q2 - Results - Earnings Call Presentation
2026-08-05. The following slide deck was published by Bioventus Inc.
NASDAQ · BVS
Bioventus Inc.
Healthcare · Medical - Devices
$13.89
Down-$0.03 (-0.18%)
Updated Aug 14, 2026, 6:23 AM
SID Score
5.8/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 495.93M
- P/E ratio
- 63.41
- Dividend yield
- 0.00%
- 52-week range
- $6.26 – $15.89
- Volume
- 632.61K
- Avg. volume
- 310.75K
Price performance
BVS price history
1M range · 21 trading sessions · Daily adjusted prices
BVS closed at $13.89 after 21 trading sessions, up 11.75% for the selected period.
- Last close
- $13.89
- Period change
- +11.75%
- Period low
- $11.48
- Period high
- $15.26
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 13, 2026 | $14.02 | $14.03 | $13.73 | $13.89 | 632.61K |
| Aug 12, 2026 | $13.78 | $14.015 | $13.485 | $13.915 | 536.55K |
| Aug 11, 2026 | $13.81 | $13.98 | $13.75 | $13.85 | 538.11K |
| Aug 10, 2026 | $13.89 | $13.99 | $13.44 | $13.96 | 917.01K |
| Aug 7, 2026 | $13.99 | $14.29 | $13.72 | $14.125 | 939.78K |
| Aug 6, 2026 | $15.01 | $15.02 | $13.72 | $13.98 | 1.52M |
| Aug 5, 2026 | $12.69 | $15.8927 | $12.68 | $15.26 | 2.53M |
| Aug 4, 2026 | $13.29 | $13.59 | $13.00 | $13.42 | 947.26K |
| Aug 3, 2026 | $13.36 | $14.00 | $13.36 | $13.47 | 1.13M |
| Jul 31, 2026 | $13.15 | $13.25 | $12.425 | $13.17 | 774.02K |
| Jul 30, 2026 | $13.13 | $13.345 | $12.9474 | $13.18 | 601.04K |
| Jul 29, 2026 | $13.03 | $13.55 | $12.93 | $13.12 | 808.53K |
| Jul 28, 2026 | $12.54 | $13.30 | $12.54 | $13.21 | 956.06K |
| Jul 27, 2026 | $12.15 | $12.49 | $11.90 | $12.45 | 823.02K |
| Jul 24, 2026 | $11.67 | $11.91 | $11.60 | $11.80 | 472.86K |
| Jul 23, 2026 | $11.53 | $11.78 | $11.40 | $11.48 | 391.23K |
| Jul 22, 2026 | $11.79 | $11.9798 | $11.61 | $11.63 | 566.1K |
| Jul 21, 2026 | $11.402 | $11.92 | $11.35 | $11.88 | 447.42K |
| Jul 20, 2026 | $12.01 | $12.01 | $11.38 | $11.58 | 825.3K |
| Jul 17, 2026 | $12.37 | $12.49 | $11.9502 | $12.06 | 609.65K |
| Jul 16, 2026 | $12.04 | $12.53 | $11.93 | $12.43 | 637.34K |
Latest BVS news
The latest Smart Investors Daily articles mentioning BVS.
Stock researchCompany · Overview
BVS research
Overview
Company profile and research snapshot.
Company profile
Bioventus Inc is a medical technology company. The company is engaged in developing and commercializing clinically differentiated treatments that engage and enhance the body's natural healing process. It offers a diverse portfolio of products to serve physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine and neurosurgery. Its portfolio of products is grouped into three verticals based on clinical use: Pain Treatments, Surgical Solutions, and Restorative Therapies. Geographical presence is in the United States which derives key revenue, and International markets.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $9.83
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jun 30, 2026 | Barrington Research | Outperform | — |
| Jun 16, 2026 | Canaccord Genuity | Buy | — |
| May 22, 2026 | Barrington Research | Outperform | — |
| Mar 6, 2026 | Craig-Hallum | Buy | — |
| Mar 6, 2026 | Barrington Research | Outperform | — |
News briefing
No generated briefing is available yet.
SeekingAlpha · Aug 5, 2026
Bioventus Inc. (BVS) Q2 2026 Earnings Call Transcript
Bioventus Inc. (BVS) Q2 2026 Earnings Call August 5, 2026 8:30 AM EDTCompany ParticipantsDavid Crawford - Vice President of Investor Relations &...
ChartMill · Aug 5, 2026
Bioventus (NASDAQ:BVS) Falls After Q2 Revenue Miss, Launches Strategic Review
Bioventus shares drop ~7% premarket on Q2 revenue miss, though EPS meets estimates; company launches strategic review.
Benzinga · Aug 5, 2026
Bioventus Q2 Adj. EPS $0.22, Inline, Sales $153.208M Miss $155.640M Estimate
Bioventus (NASDAQ:BVS) reported quarterly earnings of $0.22 per share which met the analyst consensus estimate. This is a 4.76 percent increase over earnings of $0.21 per share from the same period last year. The
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
